• Sirana Pharma
  • Am Klopferspitz 19
  • 82152 Planegg/Martinsried
  • Germany
  • moc.amrahp-anaris@ofni
Oliver von Stein

Oliver von Stein, PhD
Chief Executive Officer

About Sirana

Sirana Pharma develops microRNA (miRNA)-targeting approaches to treat aging-related and hereditary musculoskeletal diseases. This includes osteoporosis (fragile bones), sarcopenia (muscle weakness) and osteogenesis imperfecta (brittle bones). These conditions demand new and better treatments. Thus, Sirana Pharma has developed novel miRNA-based targeted modalities to treat these conditions that stimulate the formation of new bone while attenuating a pathologically elevated bone resorption. In addition, the intervention improves muscle strength and fatigue under various disease conditions, which makes it unique. Sirana Pharma received seed funding from the High-Tech Gründerfonds (HTGF), recently closed a research collaboration with Pfizer and is currently preparing a funding round with a syndicate of experienced investors.

What is your motivation?

An increasing proportion of our aging population suffers from muscle and bone diseases. In addition, there are also rare congenital skeletal diseases, which represent a significant burden for those affected. The goal of Sirana Pharma is to transfer new knowledge from academic research to clinical development. The pursued approaches open up new treatment options for various common and rare diseases that affect the musculoskeletal system. This could benefit many future patients. The developments are accompanied at an early stage by internationally recognized experts from industry and science. This improves the possibility of transferring scientific knowledge into pharmaceutical development.

“The IZB offers very good opportunities for networking and for building a biotech company. The advantages of this location are outstanding within Germany.”